Allergan chief ranked one of the top 5 CEOs in the world by Harvard Business Review

October 28, 2014

David E.I. Pyott, Allergan’s board chairman and chief executive officer (CEO) has been ranked the 4th best-performing CEO in the world by the Harvard Business Review.

Irvine, CA-David E.I. Pyott, Allergan’s board chairman and chief executive officer (CEO) has been ranked the 4th best-performing CEO in the world by the Harvard Business Review.

“Mr. Pyott was selected for this honor out of a total of 832 current CEOs in 30 countries who qualified for consideration,” according to HBR.

The complete list, which has been published in HBR’s November issue, ranks CEOs worldwide based on their performance over their entire tenure.

In case you missed it: New details about MS, uveitis link revealed in study

In compiling its list, HBR said it examined the track records of CEOs of the Standard and Poor Global 1,200 who assumed their role between 1995 and April 30, 2012. For each CEO, HBR looked at three quantitative metrics: industry-adjusted shareholder returns, country-adjusted shareholder returns, and increase in market capitalization over the CEO’s tenure.

HBR said it designed its methodology to make an objective determination of which global CEOs have had the greatest success delivering results over the long-term. Reputation and anecdote had no bearing on the outcome of the ranking, according to HBR.

 

Since becoming Allergan’s CEO in Jan. 1998, Pyott has delivered a country-adjusted shareholder return of 1,948% and an industry-adjusted shareholder return of 1,929%. Allergan’s increase in market capitalization during this same period has exceeded $50 billion.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.